Ala Abudayyeh, MD
Department of Emergency Medicine, Division of Internal Medicine
About Dr. Abudayyeh
Dr. Ala Abudayyeh is a provider in the Internal Medicine Center and an Associate Professor in Nephrology. She is board-certified in Internal Medicine and joined MD Anderson in 2012.
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Section of Nephrology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director of Clinical Research, Division of Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2003 | University of Texas-Houston Medical School, Houston, TX, USA, MD, Internal Medicine |
| 1999 | Baylor University, Waco, TX, USA, BS, Biology |
Postgraduate Training
| 2009-2011 | Nephrology Fellowship, Nephrology, Baylor College of Medicine, Houston, TX |
| 2004-2006 | Resident, Internal Medicine, Baylor College of Medicine, Houston, TX |
| 2003-2006 | Internal Medicine Resident, Baylor College of Medicine, Houston, TX |
Board Certifications
| 2017 | Nephrology |
| 2011 | American Board of Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Division of Internal Medicine, Houston Methodist Hospital, HOUSTON, TX, 2018 - Present
Assistant Professor, Department of Emergency Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2017
Visiting Professor, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, TX, 2012 - 2014
Assistant Professor, Department of General Internal Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2013
Other Appointments/Responsibilities
Co-Author, UptoDate-Kidney disease following hematopoietic cell transplantation, HOUSTON, TX, 2020 - Present
Physician, Associated Family Medicine, Orlando, FL, 2006 - 2008
Institutional Committee Activities
Member of executive Committee, Toxicity Executive Committee, 2019 - Present
Co-Chair CPI induced Renal toxcicity, DoIM TOXICITIES RESEARCH SUB GROUP, 2019 - Present
Honors & Awards
| 2018 | 2018 Top Performers (top 1% of providers nationally ranked by patients for their delivery of care), Centers for Medicare and Medicaid Services (CMS) and Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS) |
| 2017 | Excellence in patient Care nominee, Division of internal Medicine MDACC |
| 2015 | Section of Nephrology 2015 Outstanding Nephrology Faculty Award, MDACC |
| 2014 | Division of Internal Medicine faculty recognition Award, MDACC |
| 2010 | Chief, Nephrology Fellow, Baylor College of Medicine |
Selected Publications
Peer-Reviewed Articles
- Abudayyeh A, Song J, Abdelrahim M, Dahbour I, Page VD, Zhou S, Shen C, Zhao B, Pai RN, Amaram-Davila J, Manzano JG, George MC, Yennu S, Mandayam SA, Nates JL, Moss AH. Renal Replacement Therapy in Patients With Stage IV Cancer Admitted to the Intensive Care Unit With Acute Kidney Injury at a Comprehensive Cancer Center Was Not Associated With Survival. Am J Hosp Palliat Care 37(9):1049909120902115, 2020. e-Pub 2020. PMID: 31986903.
- Abudayyeh A, Lin H, Mamlouk O, Abdelrahim M, Saliba R, Rondon G, Martinez CS, Delgado R, Page V, Rajasekaran A, Sanders PW, Qazilbash M. Impact of autologous stem cell transplantation on long term renal function and associated progression-free and overall survival in multiple myeloma. Leuk Lymphoma:1-11. e-Pub 2020. PMID: 32723196.
- Mamlouk O, Lin JS, Abdelrahim M, Tchakarov AS, Glass WF, Selamet U, Buni M, Abdel-Wahab N, Abudayyeh A. Checkpoint inhibitor-related renal vasculitis and use of rituximab. J Immunother Cancer 8(2), 2020. PMID: 32718987.
- Abudayyeh A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Martinez CS, Page VD, Tarrand JJ, Kontoyiannis DP, Marin D, Oran B, Olson A, Jones R, Popat U, Champlin RE, Chemaly RF, Shpall EJ, Rezvani K. Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients. Transpl Infect Dis:e13395. e-Pub 2020. PMID: 32602954.
- Maen Abdelrahim, Marina G2, Amir H2, William FG3 and Abudayyeh A4. Acute Renal Failure Due to Vitamin C: Case Report and Review of the Literature. Journal of Cancer & Oncology, 2020.
- Sprangers B, Abudayyeh A, Latcha S, Perazella MA, Jhaveri KD. How to determine kidney function in cancer patients?. Eur J Cancer 132:141-149. e-Pub 2020. PMID: 32361629.
- Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, Kitchlu A, Shirazian S, Assal A, Vijayan A, Renaghan AD, Ortiz-Melo DI, Rangarajan S, Malik AB, Hogan JJ, Dinh AR, Shin DS, Marrone KA, Mithani Z, Johnson DB, Hosseini A, Uprety D, Sharma S, Gupta S, Reynolds KL, Sise ME, Leaf DE. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study. J Am Soc Nephrol 31(2):435-446, 2020. e-Pub 2020. PMID: 31896554.
- Strati P, Abdelrahim M, Selamet U, Page VD, Pierce SA, Verstovsek S, Abudayyeh A. Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis. Ann Hematol 98(7):1611-1616, 2019. e-Pub 2019. PMID: 31093708.
- Abdel-Wahab N, Safa H, Abudayyeh A, Johnson DH, Trinh VA, Zobniw CM, Lin H, Wong MK, Abdelrahim M, Gaber AO, Suarez-Almazor ME, Diab A. Corrections to: Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer 7(1):158, 2019. e-Pub 2019. PMID: 31234936.
- Strati P, Glass WF, Abdelrahim M, Selamet U, Tchakarov A, Workeneh BT, Verstovsek S, Abudayyeh A. Renal complications of primary myelofibrosis. Leuk Lymphoma 60(2):1-4, 2019. e-Pub 2018. PMID: 29966471.
- Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh A. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer 7(1):2, 2019. e-Pub 2019. PMID: 30612580.
- Kala J, Abudayyeh A. Magnesium: An Overlooked Electrolyte. J Emerg Med 52(5):741-743, 2017. e-Pub 2017. PMID: 28222929.
- Abudayyeh A, Hamdi A, Abdelrahim M, Lin H, Page VD, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Oran B, Chemaly RF, Ahmed S, Abudayyeh I, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Rezvani K. Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients. Transpl Infect Dis 19(1), 2017. e-Pub 2016. PMID: 27862740.
- Wanchoo R, Abudayyeh A, Doshi M, Edeani A, Glezerman IG, Monga D, Rosner M, Jhaveri KD. Renal toxicities of novel agents used for treatment of multiple myeloma. Clin J Am Soc Nephrol 12(1):176-189, 2017. e-Pub 2016. PMID: 27654928.
- Ertem FU, Zhang W, Chang K, Mohaiza Dashwood W, Rajendran P, Sun D, Abudayyeh A, Vilar E, Abdelrahim M, Dashwood RH. Oncogenic targets Mmp7, S100a9, Nppb and Aldh1a3 from transcriptome profiling of FAP and Pirc adenomas are downregulated in response to tumor suppression by Clotam. Int J Cancer 140(2):460-468, 2017. e-Pub 2016. PMID: 27706811.
- Oliver N, Luong T, Tchakarov A, Abdelrahim M, Mulanovich VE, Kontoyiannis DP, Jones R, Kebriaei P, Samuels J, Glass W, Abudayyeh A. Disseminated cryptococcal infection in allogeneic stem cell transplant patients: a rare cause of acute kidney injury. Bone Marrow Transplant 51(10):1301-1304, 2016. e-Pub 2016. PMID: 27159179.
- Abudayyeh A, Hamdi A, Lin H, Abdelrahim M, Rondon G, Andersson BS, Afrough A, Martinez CS, Tarrand JJ, Kontoyiannis DP, Marin D, Gaber AO, Salahudeen A, Oran B, Chemaly RF, Olson A, Jones R, Popat U, Champlin RE, Shpall EJ, Winkelmayer WC, Rezvani K. Symptomatic BK Virus Infection Is Associated with Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients. Am J Transplant 16(5):1492-502, 2016. e-Pub 2016. PMID: 26608093.
- Safe S, Jin UH, Morpurgo B, Abudayyeh A, Singh M, Tjalkens RB. Nuclear receptor 4A (NR4A) family - orphans no more. J Steroid Biochem Mol Biol 157:48-60, 2016. e-Pub 2015. PMID: 25917081.
- Rajasekaran A, Ngo TT, Abdelrahim M, Glass W, Podoll A, Verstovsek S, Abudayyeh A. Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib. BMC Nephrol 16:121, 2015. e-Pub 2015. PMID: 26232031.
- Abudayyeh A, Truong LD, Beck LH, Weber DM, Rezvani K, Abdelrahim M. Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction?. Clin Kidney J 8(4):440-4, 2015. e-Pub 2015. PMID: 26251713.
- Hedrick E, Lee SO, Kim G, Abdelrahim M, Jin UH, Safe S, Abudayyeh A. Nuclear Receptor 4A1 (NR4A1) as a Drug Target for Renal Cell Adenocarcinoma. PLoS One 10(6):e0128308, 2015. e-Pub 2015. PMID: 26035713.
- Nair V, Sreevalsan S, Basha R, Abdelrahim M, Abudayyeh A, Rodrigues Hoffman A, Safe S. Mechanism of Metformin-dependent Inhibition of mTOR and Ras Activity in Pancreatic Cancer: Role of Sp Transcription Factors. J Biol Chem 289(40):27692-701, 2014. e-Pub 2014. PMID: 25143389.
- Abudayyeh AA, Lahoti A, Salahudeen AK. Onconephrology: the need and the emergence of a subspecialty in nephrology. Kidney Int 85(5):1002-4, 2014. PMID: 24786870.
- Maliakal P, Abdelrahim M, Sankpal UT, Maliakal C, Baker CH, Safe S, Herrera LJ, Abudayyeh A, Kaja S, Basha R. Chemopreventive effects of tolfenamic acid against esophageal tumorigenesis in rats. Invest New Drugs 30(3):853-61, 2012. e-Pub 2011. PMID: 21197621.
- Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, Sheikh-Hamad D, Abudayyeh A, Alvarado B, Abdelrahim M. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 29(1):41-51, 2011. e-Pub 2009. PMID: 19851711.
- Papineni S, Chintharlapalli S, Abdelrahim M, Lee SO, Burghardt R, Abudayyeh A, Baker C, Herrera L, Safe S. Tolfenamic acid inhibits esophageal cancer through repression of specificity proteins and c-Met. Carcinogenesis 30(7):1193-201, 2009. e-Pub 2009. PMID: 19406933.
- Liu X, Abdelrahim M, Abudayyeh A, Lei P, Safe S. The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. Mol Cancer Ther 8(5):1207-17, 2009. e-Pub 2009. PMID: 19435870.
- Konduri S, Colon J, Baker CH, Safe S, Abbruzzese JL, Abudayyeh A, Basha MR, Abdelrahim M. Tolfenamic acid enhances pancreatic cancer cell and tumor response to radiation therapy by inhibiting survivin protein expression. Mol Cancer Ther 8(3):533-42, 2009. e-Pub 2009. PMID: 19258429.
- Cho SD, Chintharlapalli S, Abdelrahim M, Papineni S, Liu S, Guo J, Lei P, Abudayyeh A, Safe S. 5,5'-Dibromo-bis(3'-indolyl)methane induces Kruppel-like factor 4 and p21 in colon cancer cells. Mol Cancer Ther 7(7):2109-20, 2008. PMID: 18645021.
- Abdelrahim, M., Safe, S., Baker, C., Abudayyeh, A.. RNAi and Cancer: implications and application. J RNAi Gene Silencing 2(1):136-45, 2006.
Invited Articles
- Kammi J Henriksen , Jonathan J Hogan, Ala Abudayyeh , Nupur Mistry, Jay L Koyner and Kenar D Jhaveri. Case-based discussions in onco-nephrology. Journal of Onconephrology, 2020.
- Abdelrahim M, Abudayyeh A.. Renal Toxicity. Immunotherapy Adv Exp Med Biol, 2020. e-Pub 2020.
- Abudayyeh A. Onconephrology: An Evolving Field. Methodist Debakey Cardiovasc J 15(4):305-307, 2019. PMID: 31988693.
- Mamlouok M, Abudayyeh A. Cancer immunotherapy and its renal effects. Journal of Onco-Nephrology. e-Pub 2019.
- Umut Selamet and Ala Abudayyeh. Chronic Kidney Disease as a Complication of Cancer. Journal of Onconephrology, 2017.
- Finkel KW, Cohen EP, Shirali A, Abudayyeh A, American Society of Nephrology Onco-Nephrology Forum. Paraprotein-related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy. Clin J Am Soc Nephrol 11(12):2273-2279, 2016. e-Pub 2016. PMID: 27526708.
- Ala Abudayyeh & Maen Abdelrahim. Current Strategies for Prevention and Management of Stem Cell Transplant Related Urinary Tract and Voiding Dysfunction . Current Bladder Dysfunction Reports, 2015.
Abstracts
- Abudayyeh A,, Song J, Abdelrahim M, Page VD, Mandayam SA, Nates JL, Moss AH. Dialysis does not affect outcomes in stage IV cancer patients admitted to the intensive care unit with acute kidney injury at a Comprehensive Cancer Center. ASN, 2019.
- Abudayyeh A,. Impact of autologous SCT in myeloma patients on Renal Function, Progression Free Survival and Overall Survival: A longitudinal Analysis. ASN, 2019. e-Pub 2019.
- Abudayyeh A,. Incidence of AKI in Melanoma patients treated with Immune Checkpoint Inhibitors. ASN, 2019.
- Abudayyeh A,. Allo-immunity and graft rejection after checkpoint inhibitor therapy (CPI) in solid organ transplant (SOT) recipients. ASCO June 2018, Chicago, Ill. USA, 2018.
- Abudayyeh A. Checkpoint Inhibitor Therapy in Solid Organ and Allogeneic Stem Cell Transplantation: Data Mining of The Truven Health Marketscan Research Database. SITC 33rd Annual Meeting, Walter E Washington Convention Center , Wash DC Nov 9-11,2018, 2018.
- Abudayyeh A,. Development and validation of a risk assessment tool for symptomatic BKV infection. ASCO June 2018, Chicago , Ill. USA, 2018.
- Abudayyeh A, Abdelrahim M, Selamet U, Workeneh BT, Machado S, Lahoti A,Glass WF, Tchakarov A, Tannir NM,Abdel-Wahab N,Diab A. Checkpoint inhibitor induced glomerulonephritis. J Clin Oncol 36, 2018.
- Abudayyeh A, Abdelrahim M, Selamet U, Workeneh BT, Machado S, Lahoti A,Glass WF, Tchakarov A, Tannir NM,Abdel-Wahab N,Diab A. Checkpoint inhibitor induced glomerulonephritis. ASCO 2017, 2017.
- Selamet U, Ziaolhagh A, Lakhani LS, Lahoti A, Workeneh BT, Tchakarov A, Glass WF, Abudayyeh A. Nephrotoxicity of Immune Checkpoint Inhibitors: MD Anderson Cancer Center’s Experience. J Am Soc Nephrol 28:404, 2017.
- Ziaolhagh A, Selamet U, Lakhani LS, Tchakarov A, Glass WF, Abudayyeh A. Renal Complications of Hematopoietic Stem Cell Transplantation (SCT) and Glomerulopathies in Patients with Leukemia Receiving SCT: MD Anderson Cancer Center’s Experience. J Am Soc Nephrol 28:1096, 2017.
- Lakhani LS, Selamet U, Ziaolhagh A, Glass WF, Tchakarov A, Abudayyeh A. Renal biopsy results from patients with Multiple Myeloma-data from a Comprehensive National Cancer Institute: A 10 year MD Anderson Experience. J Am Soc Nephrol 28:768, 2017.
- Ziaolhagh A, Selamet U, Glass WF, Tchakarov A, Abudayyeh A. A Rare Case of Secondary Amyloidosis with Kidney and Colon involvement in Chordoma. J Am Soc Nephrol 28:191, 2017.
- Ziaolhagh A, Selamet U, Abudayyeh A. Paraneoplastic Glomerulonephritis: An Indication to Treat Low Grade Lymphoma. Am J Kidney 69(4):A105, 2017.
- Ziaolhagh A, Selamet U, Abudayyeh A. Rituximab in Combination with High Dose Steroid for Treatment of Graft versus Host Disease of the Kidney after Hematopoietic Stem Cell Transplantation. Am J Kidney 69(4):A105, 2017.
Book Chapters
- Abudayyeh A, Kalu C. Hematuria,Hemorrhagic cystitis & Obstructive Uropathy in the Cancer Patient. In: Oncologic Critical Care Textbook, 2020.
- Kalu Chukwuma and Ala Abudayyeh. Hemorrhagic Cystitis in the Critically 2 Ill Cancer Patients. In: Oncological Critical Care. Springer, 2020.
- Abudayyeh A, Abdelrahim M, Albiges L. Renal Toxicity Associated with Immune Checkpoint Inhibitors. In: SITC’s Guide to Managaing Immunotherapy Toxicity. Demos Medical Publishing - Springer Publishing: USA, 171-84, 2019.
- Selamet U, Hanna R, Rastogi A, Abudayyeh A. Chemotherapeutic Agents and the Kidney. In: Kidney Protection. Oxford University Press: USA, 2019.
- Abdelrahim M, Nash MJ, Gottipolu S, Abudayyeh A, Basha R. Anticancer activity of a small molecule, tolfenamic acid: an emphasis on pancreatic cancer. In: Theranostic Approach for Pancreatic Cancer. Elsevier, 195-210, 2019.
- Selamet U, Abudayyeh A. Dysnatremias in Cancer. In: OncoNephrology. Elsevier Inc: USA, 9, 2019.
- Rachel A.Sanford, Ala Abudayyeh, Christopher J. Logothetis, NizarM. Tannir. Urologic Complications (Chapter 129). In: Cancer Medicine, 9th edition, 2018.
- Ala Abudayyeh. Hyponatremia in cancer. In: Onconephrology, 2018.
- Selamet U, Hanna R, Rastogi A, Abudayyeh A. Chemotherapeutic Agents and the Kidney. In: Renal Protection. Oxford University Press: USA, 2018.
- Paul Sanders & Ala Abudayyeh. Dysproteinemias and Amyloidosis. In: National Kidney Foundation Primer in Kidney Diseases, 2017.
- Ala Abudayyeh & Mark A.Perazella. Onco-Nephrology: Kidney Disease in Cancer Patients. In: Comprehensive Clinical Nephrology 6th edition. 6, 2017.
- Jhaveri K, Salahudeen AK. Onco-Nephrology: Cancer, Chemotherapy and the Kidney. In: Obstruction. Springer, 2015.
- Ala Abudayyeh & Kevin Finkel. Hematological complications. In: Disorders and Kidney Disease. American Society of Nephrology. Onco-Nephrology Core Curriculum. American Society of Nephrology, 2015.
- Floege J, Johnson RJ, Feehally J. Comprehensive Clinical Nephrology . In: Renal Disease and Cancer. 5th, 2014.
- Finkel KW, Howard SC. Renal disease in cancer patients. In: electrolyte abnormailities. Elsevier Academic Press: Kidlington, UK, 2013.
- Zakaria A. Renal Diseases. In: Neurocritical Care Board Review. Demos Medical Publishing, 2013.
Grant & Contract Support
| Title: | Inactivation of the Nuclear Receptor TR3 as an Important New Drug Target for Treating RCC |
| Funding Source: | The University of Texas MD Anderson Cancer Center Kidney Cancer Research Program |
| Role: | Principal Investigator |
| Title: | A Prospective Observational Study of Urinary Biomarkers of Nephrotoxicity in Cancer Patients Receiving Cisplatin Chemotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-Principal Investigator |
| Title: | BK Virus Infection in Hematopoetic Stem Cell Transplant Survivors and Renal Outcomes |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified November 12, 2024